Articles

Find an Article

Filter articles

Showing 11 to 20 of 695 results

Analysis: Kymab’s ‘patent bargain’ clarification and why it matters

UK25-06-2020Sarah Morgan

Yesterday’s UK Supreme Court decision in Kymab v Regeneron is expected to have profound implications for innovative life sciences companies, according to lawyers. 

SPCs: a deep dive into CJEU case law

23-06-2020Katie Cambrook and Ben Millson

The CJEU’s many attempts to clarify the law around SPCs has created more questions than answers, as Katie Cambrook and Ben Millson of Bristows explain.

Lanham Act: brand owners’ current weapon of choice

11-06-2020

As opportunistic price-gougers look to capitalise on the COVID-19 pandemic, brands such as 3M have turned to trademark law to try and stop them. Brian Michalek and Erin Westbrook of Saul Ewing Arnstein & Lehr report.

Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?

EU20-05-2020Paul Williams

Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.

Royalty Pharma: welcome clarity mixed with unwelcome ambiguity

EU15-05-2020Beatriz San Martin

The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.

Will Big Pharma get the bug for microbiome therapies?

Ireland, Japan, South Korea, UK, US06-05-2020Craig Thomson, Leena Contarino and Andrew Wells

The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.

Why things could get ugly over COVID-19 patents

30-04-2020Mark Engelman

Foreign patents protecting COVID-19 treatments may stall efforts to protect citizens, says Mark Engelman of Hardwicke chambers.

COVID-19: governments look to shield companies from IP enforcement

UK23-04-2020Andrew Pitts

The UK government’s indemnifying of ventilator manufacturers is a smart solution to potential licensing obstacles, says Andrew Pitts of Mewburn Ellis.

Patent pools: should rights owners give up their IP?

21-04-2020Rory O'Neill

Pressure is building on IP owners to offer up access to technology that could help fight COVID-19. Rory O'Neill looks at some of the implications for the patent system.

Compulsory licensing in Canada—revisited

Canada21-04-2020Daphne Lainson and Nancy Pei

New legislation has been enacted to help in the efforts to deal with the COVID-19 outbreak, as Daphne Lainson and Nancy Pei of Smart & Biggar report.

Showing 11 to 20 of 695 results

LSIPR